Rexer

Quick links to important sections

Rexer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rexer

Rexer is a prescription medicine containing the active compound Mirtazapine (INN), a synthetically derived substance used primarily to modulate key chemical messengers in the brain.

Property Description
Active ingredient Mirtazapine
Form Oral Tablets, Orally Disintegrating Tablets (ODT)
Pharmacological class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Common use Mood stabilization and relief of emotional distress
Origin Synthetic compound

Mirtazapine's Unique Pharmacological Classification

Mirtazapine is classified pharmacologically as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA), a designation that highlights its distinct dual activity on the central nervous system. The compound possesses a tetracyclic chemical structure, which differentiates it from agents like the Selective Serotonin Reuptake Inhibitors (SSRIs). Its unique mechanism involves specifically enhancing the functional availability of two critical neurotransmitters, noradrenaline and serotonin, by blocking central inhibitory receptors that typically regulate their release. This specific antagonism of the histamine (H(1)) receptor is a distinguishing feature, a property which is clinically recognized for its potential to help with sleep disturbances.

Composition and Available Pharmaceutical Forms

The sole active substance in this medication is Mirtazapine, a compound formulated as a racemic mixture of its S (+) and R (–) enantiomers. As a synthetic medicine, its composition requires the integration of pharmacologically inactive excipients to ensure the stable delivery of the active component. For the oral route of administration, Mirtazapine is manufactured into two primary forms: standard Oral Tablets (film-coated, for swallowing) and Orally Disintegrating Tablets (ODT), a wafer form that offers an alternative method of ingestion.

General Therapeutic Purpose

The core purpose of Mirtazapine is to utilize its targeted dual mechanism to rebalance the activity of key neural pathways, thereby relieving emotional distress and helping to stabilize overall mood. This is often leveraged in scenarios where the patient experiences accompanying issues such as disrupted sleep or poor appetite. This unique pharmacological profile is associated with stabilizing the emotional system. By focusing specifically on noradrenergic and serotonergic activity, the medication supports a return to a more stable emotional state.

Regulatory References

  1. StatPearls

What side effects are possible with Rexer?

Possible Side Effects and Safety Information

Regulatory documentation for Mirtazapine (the active ingredient in Rexer) details a spectrum of officially documented adverse reactions and safety constraints.

Frequency-Classified Adverse Reactions

The most frequently reported side effects, as classified by regulatory authorities (e.g., EMA/ICH frequency bands):

Classification Examples of Documented Effects
Very Common (ge 1/10 users) Somnolence/Drowsiness, Increased Appetite, Weight Gain, Dry Mouth, Dizziness.
Common (ge 1/100 to < 1/10 users) Lethargy, Nausea, Constipation, Peripheral Edema (swelling), Paresthesia, Insomnia, Anxiety, Confusion.
Rare (< 1/1,000 users) Myoclonus (muscle jerks), Elevated Liver Transaminases.

Serious Adverse Reactions and Key Warnings

Officially documented serious adverse reactions and safety concerns are highlighted in the regulatory labels, organized by the affected System-Organ Class (SOC):

  • Blood and Lymphatic System Disorders: Serious events such as Agranulocytosis (severe reduction in white blood cells) and Bone Marrow Depression have been reported. Official labels advise monitoring if signs of infection (e.g., fever, sore throat) develop.
  • Psychiatric Disorders: The FDA Boxed Warning notes an increased risk of Suicidal Thoughts and Behavior in children, adolescents, and young adults (up to age 24).
  • Nervous System Disorders: The label documents the risk of Serotonin Syndrome, particularly when used with other serotonergic agents.

Safety Restrictions and Special Populations

Safety-Related Restrictions: Mirtazapine is strictly contraindicated for use concurrently with, or within 14 days of discontinuing, a Monoamine Oxidase Inhibitor (MAOI).

Population-Specific Notes: Safety documents advise caution in patients with renal or hepatic impairment, as the body's clearance of the medication is reduced. Additionally, the risk of Hyponatremia (low sodium levels) is noted, particularly in older adults.

Exposure Patterns: Effects such as somnolence and dizziness are officially noted as being more likely at treatment initiation.

The official safety information structures the understanding of risks by clearly documenting the frequency and nature of all known adverse reactions, defining non-negotiable limitations on use (contraindications), and establishing required precautions for specific patient groups.

Overdose and Emergency Response

Rexer Overdose and when to seek help

Overdosage with Mirtazapine (Rexer) primarily affects the Central Nervous System (CNS) and the cardiovascular system, according to official regulatory documentation. Documented manifestations may include symptoms such as drowsiness, disorientation, and impaired memory, escalating to more severe signs like confusion, agitation, myoclonus, seizures, and coma. Tachycardia (rapid heart rate) is also a documented clinical sign in overdose situations.

A potentially life-threatening complication that may arise is Serotonin Syndrome. Furthermore, regulatory labels document the risk of serious cardiac effects, specifically QT prolongation and Torsades de Pointes. Fatalities have been reported, predominantly in cases where Mirtazapine was taken in a mixed overdose with other agents.

If overdose is suspected, urgent medical attention is required. Immediate medical help must be sought if the patient is experiencing severe symptoms such as collapse, difficulty breathing, an irregular heartbeat, or is unable to be awakened, as stated in government guidance. Treatment consists of general supportive and symptomatic measures, as no specific antidote is known. Monitoring of cardiac rhythm and vital signs is required during management. Regulatory documents also note that the severity of overdose may be increased in patients with moderate to severe renal or hepatic impairment.

Therapeutic Uses of Rexer

Mirtazapine is commonly used to help with symptoms related to affective disorders, applied in addressing both core emotional distress and specific physical symptoms. It is relevant in contexts marked by increased discomfort or tension where additional symptomatic support is needed.

The medication is primarily indicated for the treatment of Major Depressive Disorder (MDD). It plays a role in managing symptoms that interfere with daily functioning, including persistent low mood, sadness, and the loss of interest or pleasure (anhedonia). The medication is also utilized to help with disruptive insomnia and symptoms related to appetite loss.

This medication is generally used when previous treatments have been insufficient or when symptoms cluster into a pattern (e.g., depression with concurrent severe insomnia) requiring supportive symptom management. It offers symptomatic relief that helps maintain a sense of stability when symptoms are more noticeable and interfere with routine activities.

Quick Fact: Relief for Co-occurring Symptoms
Rexer is considered relevant in situations where patients experience emotional distress accompanied by pronounced difficulty falling asleep or appetite loss, assists with easing the overall symptom load alongside the mood symptoms.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rexer (Mirtazapine) — Official Regulatory Information


Eligibility Scope

Classification Population Group/Condition
Approved Use Adults (18 years and older)
Not Approved Children and Adolescents (under 18 years)
Contraindicated Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days of stopping MAOIs
Contraindicated Known hypersensitivity to Mirtazapine or its excipients

Age- and Condition-Based Restrictions

Eligibility Status Specific Population/Condition
Caution Indicated Older Adults (Geriatric patients) due to reduced clearance and risk of confusion
Caution Indicated Moderate to severe renal or hepatic impairment due to decreased drug clearance
Conditional Use Patients with a history of seizures/epilepsy, mania/hypomania, or QT prolongation risk factors
Pregnancy/Lactation Use only if clearly needed during pregnancy; caution during lactation as the drug is excreted in small amounts

Connection to the Overall Eligibility Profile

Official regulatory documents define Mirtazapine eligibility by establishing absolute prohibitions (contraindications like MAOI use) and an age-based exclusion (not approved for patients under 18 years of age). Use is further constrained by conditional restrictions, mandating caution in populations with impaired organ function (renal/hepatic) or pre-existing comorbidities like cardiovascular risk or a history of seizures, as stated in the product labeling.

What should I know about interactions with other medicines?

The official interaction profile for Rexer (Mirtazapine) establishes specific constraints based on pharmacodynamic reinforcement and pharmacokinetic alteration.

Contraindicated and Time-Separated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, is formally contraindicated due to the official risk of serious reactions. A mandatory 14-day separation period must elapse after discontinuing either Mirtazapine or an MAOI before initiating the other, as stated in regulatory documents.

Pharmacodynamic and Substance Interactions

Concomitant use with other serotonergic drugs (such as Triptans or the herbal supplement St. John's Wort) increases the documented risk of Serotonin Syndrome. Co-administration with alcohol and other CNS depressants results in an officially stated additive effect on sedation. The use with Warfarin is documented to require monitoring of INR (International Normalized Ratio) due to the potential for increased anticoagulant activity.

Pharmacokinetic Alteration of Exposure

Pharmacokinetic changes are primarily mediated by the CYP3A4 enzyme. Strong inhibitors of this enzyme, such as Ketoconazole and Clarithromycin, are documented to increase Mirtazapine plasma exposure, while strong inducers like Carbamazepine officially decrease it. This alteration in systemic exposure warrants the consideration of regulatory dosage adjustments. Mirtazapine clearance is also documented to be reduced in patients with moderate to severe renal or hepatic impairment, resulting in a population-specific increase in exposure.

Mechanism of Action

Rexer's (Mirtazapine) mechanism of action is defined by a distinct set of receptor antagonisms that collectively modulate key neurotransmitter systems in the central nervous system (CNS), resulting in alterations to specific physiological signaling pathways.

Dual Enhancement Through Presynaptic Antagonism

This domain describes the core mechanism of action, where the medication acts as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA) by blocking central presynaptic alpha2-adrenergic autoreceptors and heteroreceptors. This antagonism effectively removes the normal inhibitory brake on the release of both Noradrenaline (NE) and Serotonin (5-HT), initiating a cascade that leads to an increase in the extracellular concentration of both neurotransmitters in the synaptic space.

Targeted Serotonin Signaling and Arousal Modulation

The mechanism also involves antagonism of postsynaptic 5-HT2 A, 5-HT2 C, and 5-HT3 serotonin receptors, channeling the increased supply of 5-HT to the 5-HT1 A receptor pathways. Concurrently, antagonism of the central H1 (histamine) receptor dampens histamine-driven neural activity in arousal centers, promoting a shift toward reduced CNS alertness and modulating the physiological state associated with wakefulness.

Dosage and Administration Information

Mirtazapine is administered exclusively by the oral route, available as film-coated tablets and orally disintegrating tablets (ODT or SolTab) in strengths up to 45 mg. The standard regimen for adults typically begins with an initial amount of 15 mg taken once daily. The effective daily range may extend from 15 mg up to a maximum recommended amount of 45 mg per day.

The medication is generally taken in the evening before sleep and may be administered with or without food. The official dose adjustment schedule requires that any changes to the daily amount are made at intervals of not less than 1 to 2 weeks to appropriately assess the current dosage.

Procedural instructions apply to the different forms: standard tablets must be swallowed whole, while ODTs should be handled with dry hands, placed on the tongue to dissolve immediately upon opening the blister pack, and swallowed with saliva, not water.

Official guidelines also mandate usage modifications for certain populations. Clearance is reduced in older adults, who may require a lower starting amount (e.g., 7.5 mg), and individuals with moderate to severe hepatic or renal impairment may necessitate a dose decrease. Mirtazapine is not approved for use in pediatric patients. When discontinuing treatment, the dosage must be reduced gradually rather than stopping abruptly, defining the required procedural structure for treatment cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Rexer

Evidence for Use in Major Depressive Disorder (MDD)

Core research involves randomized controlled trials (RCTs) over short periods, typically 6 to 12 weeks. These studies monitored symptom intensity and response rates, exploring the difference in measured symptoms between the medicine group and those receiving placebo. However, the short follow-up durations mean that the full characterization of long-term outcomes remains uncertain.

Evidence for Depression with Co-occurring Symptoms (Sleep and Appetite)

Research has explored Mirtazapine in patients presenting with sleep disturbances or appetite loss. Studies highlight patterns observed related to increased appetite and associated weight gain. For sleep, studies described changes in time to fall asleep and total sleep duration. Dedicated, large-scale RCTs focusing solely on these co-occurring symptoms are limited.

Evidence for Use as Augmentation Therapy

Mirtazapine was studied as an augmentation strategy, where it was added to an existing antidepressant regimen for patients with an unsatisfactory outcome. Findings were mixed: some trials reported lower depressive symptom scores under the combination therapy, while others did not find a clear difference in primary outcomes. Comparative evidence with other augmentation options is lacking.

Long-Term Studies and Follow-up Data

Initial regulatory research focuses mainly on short-term changes. While some trials include maintenance phases, long-term effects are not fully established through extensive placebo-controlled trials over many years. Follow-up durations were limited in the core evidence base, and the sustained durability of outcomes is not well characterized.

Evidence in Special Populations

The majority of research was evaluated in adult populations. Studies noted that the medicine's clearance may be slower in older adults. Regulatory reviews emphasize that research focusing on safety and effectiveness is insufficient for children and adolescents. Available research for pregnant women and nursing mothers remains limited, making interpretation of outcomes challenging for this group.

Key Studies & References

  1. The effects of mirtazapine on sleep in patients with major depressive disorder
  2. Mirtazapine (StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Rexer (FAQ)


Q: How long does it typically take for Rexer to start working?

Regulatory documents indicate that the initial antidepressant effect usually begins to appear after one to two weeks of using the medication. Clinical documentation indicates that an assessment of response is typically made after two to four weeks of treatment at an appropriate amount.


Q: Is Rexer a type of antidepressant?

Yes, mirtazapine (Rexer) is classified as an atypical antidepressant. Official product information defines its actions, which involve modulating the release and effects of certain chemicals in the brain, such as noradrenaline and serotonin.


Q: Are there any foods or drinks that should be avoided while on Rexer?

Official information indicates that alcohol use during treatment is associated with increased central nervous system (CNS) effects, such as making you feel drowsy or dizzy, and its consumption is therefore advised against or limited. There are no general prohibitions regarding specific foods.


Q: Can Rexer be taken long-term?

Clinical studies established the medication's effectiveness over several weeks, and official prescribing information advises that treatment should typically be continued for four to nine months after symptoms initially respond. Regulatory documents indicate that if treatment continues beyond this period, continued appropriateness should be determined through re-evaluation.


Q: Is Rexer safe for older adults?

Mirtazapine is available for use in older adults, but regulatory information emphasizes the need for caution. This is due to reduced clearance and an increased risk of side effects, including low sodium levels (hyponatremia). Lower starting amounts may be necessary.


Q: How does Rexer affect sleep?

The medication is typically taken in the evening before sleep, which is consistent with its sedating properties. Regulatory documents note that both somnolence (drowsiness) and insomnia (difficulty sleeping) have been reported as side effects.


Q: Are there warnings about driving while taking Rexer?

Official information advises patients that operating heavy machinery or driving may be impaired due to the risk of drowsiness and dizziness. Caution is necessary until a patient understands the medication’s effects on their ability to think, react, and coordinate safely.


Q: Does Rexer require any special monitoring or testing?

Official safety information notes that signs of infection (such as fever or a sore throat) should be monitored due to the risk of a serious, rare decrease in white blood cells (agranulocytosis). Additionally, monitoring of weight and lipid levels is generally recommended during treatment.


Q: Can Rexer be crushed or split?

Standard film-coated tablets are intended to be swallowed whole according to official guidelines. The orally disintegrating tablets (ODTs) are specifically designed to dissolve on the tongue and are not intended to be split or crushed. Modification of tablets is not covered in the general administration instructions.


Q: Are there common signs that Rexer is working?

Official patient information indicates that changes in symptoms such as sleep and appetite are commonly reviewed during the first one to two weeks. The full desired effect on mood and interest in activities may take longer, typically between four and twelve weeks.


Q: What conditions make someone ineligible to take Rexer?

Official documents describe two formal contraindications for use: if a patient has a known allergy to mirtazapine, or if they are taking or have recently stopped (within 14 days) a Monoamine Oxidase Inhibitor (MAOI). Regulatory documents also indicate a need for caution in patients with a history of seizures, heart problems, or low blood pressure.


Q: What is the main reason doctors prescribe Rexer?

The drug is officially indicated by regulatory bodies for the treatment of Major Depressive Disorder (MDD) in adults.


Q: Does Rexer have a generic version available?

Yes, mirtazapine is available as a generic version. The U.S. Food and Drug Administration (FDA) has approved generic mirtazapine tablets for use.


Q: Can Rexer affect blood pressure?

Yes, official safety information indicates that mirtazapine is associated with a risk of orthostatic hypotension (a drop in blood pressure when changing position, like standing up). Regulatory documents indicate the need for caution in patients with existing low blood pressure or certain heart conditions.


Q: What happens if I forget to take my Rexer dose?

Official drug labels contain specific instructions for what to do in the event of a missed dose. These instructions provide guidance on timing and emphasize that the amount taken should not be doubled to make up for the missed dose.


Q: What should I do if a side effect of Rexer bothers me?

Official patient information explains that contact with a healthcare provider is recommended if side effects persist or become bothersome. Contact is also noted if signs of a potentially serious adverse event are noted, such as a fever or infection.


Q: Is Rexer available over the counter?

No, mirtazapine is classified as a prescription-only medicine in the United States and other major health regions, meaning a physician's authorization is required to obtain it.


Q: Can Rexer be taken with pain relievers like ibuprofen?

Official drug interaction information does not list a direct interaction with ibuprofen, but regulatory information indicates a need for caution when combining Rexer with medicines that may increase the risk of gastrointestinal bleeding or affect blood pressure.


Q: Is it normal to have vivid dreams on Rexer?

Yes, abnormal dreams are a documented side effect listed in official adverse reaction profiles for mirtazapine. This can include experiences of vivid, unusual, or unpleasant dreams.


Q: Is Rexer a controlled substance?

No, mirtazapine is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This indicates it does not have a high potential for abuse or dependence.


Q: How long does Rexer stay in the body after the last dose?

Regulatory pharmacokinetic properties indicate that the elimination half-life of mirtazapine is typically between 20 to 40 hours. The half-life refers to the time it takes for the concentration of the medication in the body to decrease by half.


Q: Is it possible for Rexer to stop working after a while?

Clinical studies performed during continuation phases of treatment generally showed sustained efficacy. Tolerance or loss of effect is not commonly reported over the recommended treatment duration. If symptoms return, a medical review is indicated.


Q: Does Rexer have any interactions with birth control pills?

Some drug interaction references suggest that mirtazapine may interact with certain oral contraceptives. This interaction can potentially alter the amount of mirtazapine in the body, which may lead to an increase in common side effects like drowsiness or dizziness.


Q: Can men and women use Rexer for the same conditions?

Yes, official indications for mirtazapine state that it is approved for the treatment of Major Depressive Disorder (MDD) in adults regardless of sex.


Q: Is Rexer approved in other countries besides the US?

Yes, mirtazapine has received regulatory approval and is used in many countries worldwide, including nations in the European Union (EU) and Canada. This is confirmed by the availability of official product information from multiple regulatory bodies.


Q: Can Rexer be taken if I have diabetes?

Mirtazapine is available for use by patients with diabetes mellitus, but regulatory warnings indicate a need for caution. Antidepressants may affect blood sugar control, and monitoring of blood sugar levels may be necessary during treatment.


Q: Is Rexer addictive or habit-forming?

Rexer is not classified as having a high potential for abuse and is not considered highly addictive. However, regulatory warnings exist regarding the need for a gradual dose reduction when stopping treatment to manage potential discontinuation symptoms.


Q: Does Rexer show up on a standard drug screening test?

Mirtazapine is not typically included in standard, routine drug screens, such as common 5- or 10-panel tests. However, it can be specifically detected through specialized laboratory tests if they are ordered for monitoring therapeutic drug levels.

How should Rexer be stored and disposed of?

How to Store and Dispose of Rexer?

Storage Requirements

Rexer should be stored in its closed container at room temperature, away from excessive heat, moisture, and direct light. It is essential to protect the medicine from freezing. The orodispersible tablets must be kept in the original blister or container pack until immediate use. Once a dose is removed from the blister, it must be taken right away and cannot be stored.

Disposal Instructions

To dispose of unused or expired Rexer, follow official guidelines to keep the medicine out of the reach of children and pets. The preferred method is using a secure drug take-back program or a drug mail-back service. If these options are not available, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) in a sealed bag and thrown into the household trash. Do not dispose of this medicine by flushing it down a toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rexer found in:

A-Z Index: